EDGAR Filing Documents for 0001636050-19-000098

Form 8-K - Current report:

SEC Accession No. 0001636050-19-000098

Filing Date

2019-11-08

Accepted

2019-11-08 16:53:44

Documents

Period of Report

2019-11-04

Items

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	axovant1108198-k_2.htm	8-K	46977
2	EXHIBIT 10.1	axgt1108198k_2xexhibit101.htm	EX-10.1	70477
3	EXHIBIT 10.2	axgt1108198k_2xexhibit102.htm	EX-10.2	71659
4	EXHIBIT 10.3	axgt1108198k_2xexhibit103.htm	EX-10.3	69875
	Complete submission text file	0001636050-19-000098.txt		260511

Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036

Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708

Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 191204745
SIC: 2834 Pharmaceutical Preparations